In summary, the targeting of LGALS4 or MTHFD, in combination with ADT, chemotherapy, and immunotherapy, could offer a novel approach to treating prostate cancer, particularly in cases where resistance to current therapies limits clinical efficacy. This evidence concerns the gene MTHFD1 and prostate carcinoma.